1. Health

Discuss in my forum

Carol Eustice

FDA Pushes Back Decision on Rheumatoid Arthritis Drug Tofacitinib

By August 29, 2012

Follow me on:

The U.S. Food and Drug Administration has extended the date when they will act on the New Drug Application for tofacitinib by three months. The decision regarding tofacitinib was expected August 21, 2012. Tofacitinib is an oral treatment for adults with moderately to severely active rheumatoid arthritis. The drug has been highly anticipated. If the FDA approves tofacitinib, it will be the first rheumatoid arthritis treatment in a new class of drugs known as Janus kinase (JAK) inhibitors.

The decision was postponed when the FDA determined that additional data analyses recently submitted by Pfizer required more time to review. The decision is now expected by November 21, 2012.

Related Articles:

Follow Me:

Facebook | Twitter | Message Board | Newsletter

Photo by David Sucsy (iStockphoto)

Comments
September 10, 2012 at 3:17 pm
(1) Affiliate Marketing says:

Normally I do not read post on blogs, however I would like to say
that this write-up very forced me to check out and do so!
Your writing taste has been amazed me. Thanks, quite
nice post.

Leave a Comment

Line and paragraph breaks are automatic. Some HTML allowed: <a href="" title="">, <b>, <i>, <strike>

©2014 About.com. All rights reserved.

We comply with the HONcode standard
for trustworthy health
information: verify here.